The Effect of Exercise and Tirzepatide on Weight and Health Outcomes (EXER-MED)

NCT07298915 on ClinicalTrials.gov · last registry update 2026-05-06

A small phase 3 — 24 participants, against a typical 424. Due to report December 2026, alongside 31 other tracked readouts that quarter. Primary outcome, as filed: Weight. Sponsors move these dates routinely; any movement since this site started watching is listed below. tirzepatide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status: NOT_YET_RECRUITING
Phase: P3
Drug: tirzepatide
Mounjaro, Zepbound
Sponsor: University of Virginia
Sponsor type: Other
Enrollment: 24
Started: 2026-08
Primary completion: 2026-12 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Weight

Conditions studied

Obesity & Overweight

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.